Answers are grounded in this paper and cite their sources.
A novel observation finds systemic chemotherapy may regress ocular surface neoplasia in a patient with lung cancer, implying new treatment avenues.
Ocular surface squamous neoplasia (OSSN) is the most common non-melanomatous ocular surface malignancy affecting the conjunctival and corneal epithelium typically managed with topical chemotherapeutic agents as first-line treatment, with surgical excision reserved for refractory cases or when topical therapy is contraindicated. We describe a rare case of clinically diagnosed OSSN in a 69-year-old male undergoing systemic chemotherapy with Pemetrexed and Amivantamab for metastatic non-small cell lung carcinoma, who exhibited complete spontaneous regression of the conjunctival lesion without direct ocular treatment. The lesion’s clinical and anterior segment OCT features were consistent with OSSN. The temporal correlation may suggest a potential systemic antineoplastic effect of the chemotherapy agents, particularly through inhibition of epidermal growth factor receptor (EGFR) and MET pathways and antiproliferative action on dysplastic epithelial cells. This case highlights the possibility of systemic chemotherapy influencing secondary ocular surface neoplasia, emphasizing the importance of multidisciplinary care and further research into systemic treatments for OSSN.
No takes yet. Share an insight, caveat, or question.
Arunkumar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: